Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 20.50 GBp
Change Today -0.50 / -2.38%
Volume 93.5K
VAL On Other Exchanges
As of 11:30 AM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

24 Greville Street

London, EC1N 8SS

United Kingdom



ValiRx plc, a biopharmaceutical company, develops novel technologies and products in oncology therapeutics and diagnostics in the United Kingdom and rest of Europe. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of genes by targeted histone deacetylation that leads to chromatin condensation. The company’s lead drug candidates include VAL201, an anti-cancer therapeutic that is in Phase I/II trials used for the treatment of prostate cancer and other indications of hormone induced unregulated growth, including endometriosis; and VAL401, the reformulation of a generic drug, which is in pre-clinical stage for the treatment of lung cancer and other oncology indications. Its drug candidates also comprise VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that is implicated carcinomas. In addition, the company engages in the development of NAV3, a cancer screening test, which is in Phase I clinical trials for the detection of cancer cells in tissue samples. ValiRx plc was incorporated in 2000 and is based in London, the United Kingdom.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 20.50 GBp -0.50

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies

Industry Analysis


Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.9x
Price/Book 2.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VALIRX PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at